Allogene Therapeutics, Inc. (NASDAQ:ALLO) Insider Timothy L. Moore Sells 14,746 Shares

Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) insider Timothy L. Moore sold 14,746 shares of Allogene Therapeutics stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $1.71, for a total value of $25,215.66. Following the transaction, the insider now directly owns 250,713 shares in the company, valued at approximately $428,719.23. The trade was a 5.55 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Allogene Therapeutics Price Performance

Shares of NASDAQ:ALLO traded down $0.09 during trading on Friday, hitting $1.51. 2,397,116 shares of the company were exchanged, compared to its average volume of 2,560,674. The company has a market cap of $316.60 million, a PE ratio of -0.97 and a beta of 0.83. Allogene Therapeutics, Inc. has a 52-week low of $1.50 and a 52-week high of $5.78. The stock has a 50 day moving average of $2.01 and a 200 day moving average of $2.42.

Wall Street Analyst Weigh In

ALLO has been the topic of a number of analyst reports. William Blair reaffirmed an "outperform" rating on shares of Allogene Therapeutics in a report on Thursday, November 14th. HC Wainwright restated a "buy" rating and set a $9.00 price target on shares of Allogene Therapeutics in a report on Friday, November 8th. Finally, Piper Sandler decreased their price objective on shares of Allogene Therapeutics from $11.00 to $9.00 and set an "overweight" rating for the company in a research note on Thursday, November 14th. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to MarketBeat.com, Allogene Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $9.73.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC increased its position in shares of Allogene Therapeutics by 14.4% during the third quarter. Geode Capital Management LLC now owns 3,227,104 shares of the company's stock valued at $9,037,000 after buying an additional 407,070 shares during the period. Dimensional Fund Advisors LP increased its holdings in Allogene Therapeutics by 24.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,550,640 shares of the company's stock worth $5,944,000 after acquiring an additional 507,021 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in Allogene Therapeutics by 0.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,188,838 shares of the company's stock worth $2,532,000 after purchasing an additional 9,990 shares in the last quarter. Zacks Investment Management purchased a new position in shares of Allogene Therapeutics during the 3rd quarter valued at $1,446,000. Finally, The Manufacturers Life Insurance Company increased its holdings in shares of Allogene Therapeutics by 1.2% in the third quarter. The Manufacturers Life Insurance Company now owns 486,023 shares of the company's stock worth $1,361,000 after purchasing an additional 5,642 shares during the period. Institutional investors own 83.63% of the company's stock.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).